MagVenture wins FDA clearance for OCD TMS treatment device

MagVenture announced that it received FDA clearance for its TMS Therapy for adjunct treatment of obsessive-compulsive disorder (OCD).

Alpharetta-Ga.-based MagVenture said in a news release that the authorization is its second from the FDA, having already been cleared for its treatment of major depressive disorder.

TMS Therapy uses magnetic pulses to stimulate a specific area of the brain in an effort to improve OCD symptoms, having already been well-established as an option for major depressive disorder.

The adjunct treatment to existing OCD therapies may involve pharmaceutical and behavioral therapy, and is an out-patient procedure with no systemic side effects, MagVenture said. The treatment specifically targets networks in the brain that are known to be particularly affected by OCD.

“We have worked closely with brain researchers for well over 25 years, providing numerous TMS solutions to help advance the field of neuroscience – both basic and applied,” MagVenture VP of sales Kerry Rome said in the release. “Expanding the treatment options to include other indications than major depressive disorder, such as OCD, is one more important step towards helping more adult patients improve their mental health.”